The global lung injury market was valued at $1,579.47 in 2020, and is projected to reach $2,417.41 by 2030 registering a CAGR of 4.20% from 2021 to 2030.
Lung injury is a disorder of acute inflammation that causes disruption of the lung endothelial and epithelial barriers. Often it becomes a life-threatening condition caused by severe acute hypoxemic respiratory failure. In addition, it is a key reason of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. This type of injury has a significant impact on public health, with high incidence rate across the world. Moreover, it requires administration of rapid and goal-oriented therapy to prevent further lung damage.
The growth of the global lung injury market is majorly driven by rise in prevalence of lung-related diseases and increase in geriatric population. Furthermore, increase in awareness related to treatment of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is expected to notably contribute toward the growth of the global market. However, complications associated with the use of therapies and low adoption rate due to these complications hinder the market growth. On the contrary, pipeline drugs for the treatment of acute lung injury are being studied in late phase of clinical trials. . These drugs are likely to be available in the market in next few years, which is expected to offer remunerative opportunity for the expansion of the market during the forecast period.
The global lung injury market is segmented into therapy, injury type, end user, and region. Depending on therapy, the market is bifurcated into medication and devices. The medication segment is further categorized into pharmacotherapy, fluid management, and inhaled nitric oxide. Moreover, the devices is subdivided into mechanical ventilation and adjunctive procedures devices. On the basis of injury type, the market is segregated into direct injury and indirect injury. By end user, it is fragmented into hospitals & clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Lung injury is a disorder of acute inflammation that causes disruption of the lung endothelial and epithelial barriers. Often it becomes a life-threatening condition caused by severe acute hypoxemic respiratory failure. In addition, it is a key reason of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. This type of injury has a significant impact on public health, with high incidence rate across the world. Moreover, it requires administration of rapid and goal-oriented therapy to prevent further lung damage.
The growth of the global lung injury market is majorly driven by rise in prevalence of lung-related diseases and increase in geriatric population. Furthermore, increase in awareness related to treatment of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is expected to notably contribute toward the growth of the global market. However, complications associated with the use of therapies and low adoption rate due to these complications hinder the market growth. On the contrary, pipeline drugs for the treatment of acute lung injury are being studied in late phase of clinical trials. . These drugs are likely to be available in the market in next few years, which is expected to offer remunerative opportunity for the expansion of the market during the forecast period.
The global lung injury market is segmented into therapy, injury type, end user, and region. Depending on therapy, the market is bifurcated into medication and devices. The medication segment is further categorized into pharmacotherapy, fluid management, and inhaled nitric oxide. Moreover, the devices is subdivided into mechanical ventilation and adjunctive procedures devices. On the basis of injury type, the market is segregated into direct injury and indirect injury. By end user, it is fragmented into hospitals & clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global lung injury market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps understand the applications and products of lung injury used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Therapy
- Medication
- Pharmacotherapy
- Fluid Management
- Inhaled nitric oxide
- Devices
- Mechanical Ventilation
- Adjunctive Procedures Devices
By Injury Type
- Direct Injury
- Indirect Injury
By End User
- Hospitals & Clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of lung-related diseases
3.5.1.2. Surge in geriatric population
3.5.1.3. Increase in adoption of new technologies with availability of high number of drugs used in lung injury treatment
3.5.1.4. Recent advancements in research related to treatment of acute lung injury
3.5.2. Restraint
3.5.2.1. High cost of therapies coupled with lack of established treatment
3.5.3. Opportunity
3.5.3.1. New developments in therapies
3.5.4. Impact analysis
3.6. COVID-19 impact analysis on the lung injury market
CHAPTER 4: LUNG INJURY MARKET, BY THERAPY4.1. Overview
4.1.1. Market size and forecast
4.2. Medication
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.2.4. Market size and forecast, by type
4.2.4.1. Pharmacotherapy
4.2.4.1.1. Market size and forecast
4.2.4.1.2. Lung injury pharmacotherapy market size and forecast, by region
4.2.4.1.3. Lung injury pharmacotherapy market size and forecast, by country
4.2.4.2. Fluid management
4.2.4.2.1. Market size and forecast
4.2.4.2.2. Lung injury fluid management market size and forecast, by region
4.2.4.2.3. Lung injury fluid management market size and forecast, by country
4.2.4.3. Inhaled nitric oxide
4.2.4.3.1. Market size and forecast
4.2.4.3.2. Lung injury inhaled nitric oxide market size and forecast, by region
4.2.4.3.3. Lung injury Inhaled nitric oxide market size and forecast, by country
4.3. Devices
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.4. Market size and forecast, by type
4.3.4.1. Mechanical ventilation
4.3.4.1.1. Market size and forecast
4.3.4.1.2. Lung injury mechanical ventilation market size and forecast, by region
4.3.4.1.3. Lung injury mechanical ventilation market size and forecast, by country
4.3.4.2. Adjunctive procedures devices
4.3.4.2.1. Market size and forecast
4.3.4.2.2. Lung injury adjunctive procedures devices market size and forecast, by region
4.3.4.2.3. Lung injury adjunctive procedures devices market size and forecast, by country
CHAPTER 5: LUNG INJURY MARKET, BY INURY TYPE5.1. Overview
5.1.1. Market size and forecast
5.2. Direct injury
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Indirect injury
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
CHAPTER 6: LUNG INJURY MARKET, BY END USER6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals & clinics
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Others
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
CHAPTER 7: LUNG INJURY MARKET, BY REGION7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S. lung injury market, by therapy
7.2.2.2. U.S. lung injury market, by injury type
7.2.2.3. U.S. lung injury market, by end user
7.2.2.4. Canada lung injury market, by therapy
7.2.2.5. Canada lung injury market, by injury type
7.2.2.6. Canada lung injury market, by end user
7.2.2.7. Mexico lung injury market, by therapy
7.2.2.8. Mexico lung injury market, by injury type
7.2.2.9. Mexico lung injury market, by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany lung injury market, by therapy
7.3.2.2. Germany lung injury market, by injury type
7.3.2.3. Germany lung injury market, by end user
7.3.2.4. France lung injury market, by therapy
7.3.2.5. France lung injury market, by injury type
7.3.2.6. France lung injury market, by end user
7.3.2.7. UK lung injury market, by therapy
7.3.2.8. UK lung injury market, by injury type
7.3.2.9. UK lung injury market, by end user
7.3.2.10. Italy lung injury market, by therapy
7.3.2.11. Italy lung injury market, by injury type
7.3.2.12. Italy lung injury market, by end user
7.3.2.13. Spain lung injury market, by therapy
7.3.2.14. Spain lung injury market, by injury type
7.3.2.15. Spain lung injury market, by end user
7.3.2.16. Rest of Europe lung injury market, by therapy
7.3.2.17. Rest of Europe lung injury market, by injury type
7.3.2.18. Rest of Europe lung injury market, by end user
7.3.3. Europe lung injury market, by therapy
7.3.4. Europe lung injury market, by injury type
7.3.5. Europe lung injury market, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan lung injury market, by therapy
7.4.2.2. Japan lung injury market, by injury type
7.4.2.3. Japan lung injury market, by end user
7.4.2.4. China lung injury market, by therapy
7.4.2.5. China lung injury market, by injury type
7.4.2.6. China lung injury market, by end user
7.4.2.7. Australia lung injury market, by therapy
7.4.2.8. Australia lung injury market, by injury type
7.4.2.9. Australia lung injury market, by end user
7.4.2.10. India lung injury market, by therapy
7.4.2.11. India lung injury market, by injury type
7.4.2.12. India lung injury market, by end user
7.4.2.13. South Korea lung injury market, by therapy
7.4.2.14. South Korea lung injury market, by injury type
7.4.2.15. South Korea lung injury market, by end user
7.4.2.16. Rest of Asia-Pacific lung injury market, by therapy
7.4.2.17. Rest of Asia-Pacific lung injury market, by injury type
7.4.2.18. Rest of Asia-Pacific lung injury market, by end user
7.4.3. Asia-Pacific lung injury market, by therapy
7.4.4. Asia-Pacific lung injury market, by injury type
7.4.5. Asia-Pacific lung injury market, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil lung injury market, by therapy
7.5.2.2. Brazil lung injury market, by injury type
7.5.2.3. Brazil lung injury market, by end user
7.5.2.4. Saudi Arabia lung injury market, by therapy
7.5.2.5. Saudi Arabia lung injury market, by injury type
7.5.2.6. Saudi Arabia lung injury market, by end user
7.5.2.7. South Africa lung injury market, by therapy
7.5.2.8. South Africa lung injury market, by injury type
7.5.2.9. South Africa lung injury market, by end user
7.5.2.10. Rest of LAMEA lung injury market, by therapy
7.5.2.11. Rest of LAMEA lung injury market, by injury type
7.5.2.12. Rest of LAMEA lung injury market, by end user
7.5.3. LAMEA lung injury market, by therapy
7.5.4. LAMEA lung injury market, by injury type
7.5.5. LAMEA lung injury market, by end user
CHAPTER 8: COMPANY PROFILES8.1. APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Key strategic moves and developments
8.2. BAYER AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. GENERAL ELECTRIC COMPANY
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. GLAXOSMITHKLINE PLC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. KONINKLIJKE PHILIPS N. V
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. LINDE PLC
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. MEDTRONIC PLC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. ONY BIOTECH INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.9. PFIZER INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
List of Tables
TABLE 01. LIST OF PIPELINE DRUGS CURRENTLY STUDIED/REGISTERED IN THE CLINICAL TRIAL FOR ACUTE LUNG INJURY OR ACUTE RESPIRATORY STRESS DISORDER IN COVID-19
TABLE 02. LUNG INJURY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 03. MEDICATION LUNG INJURY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04. LUNG INJURY MEDICATION MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 05. LUNG INJURY PHARMACOTHERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06. LUNG INJURY PHARMACOTHERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 07. LUNG INJURY FLUID MANAGEMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 08. LUNG INJURY FLUID MANAGEMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 09. LUNG INJURY INHALED NITRIC OXIDE MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 10. LUNG INJURY INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 11. LUNG INJURY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 12. LUNG INJURY DEVICES MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 13. LUNG INJURY MECHANICAL VENTILATION MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 14. LUNG INJURY MECHANICAL VENTILATION MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 15. LUNG INJURY ADJUNCTIVE PROCEDURES DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 16. LUNG INJURY ADJUNCTIVE PROCEDURES DEVICES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 17. LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030 ($MILLION)
TABLE 18. DIRECT LUNG INJURY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19. INDIRECT LUNG INJURY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 20. LUNG INJURY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 21. LUNG INJURY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2030 ($MILLION)
TABLE 22. LUNG INJURY MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 23. LUNG INJURY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 24. NORTH AMERICA LUNG INJURY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 25. U.S. LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 26. U.S. LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 27. U.S. LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 28. CANADA LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 29. CANADA LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 30. CANADA LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 31. MEXICO LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 32. MEXICO LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 33. MEXICO LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 34. EUROPE LUNG INJURY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 35. GERMANY LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 36. GERMANY LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 37. GERMANY LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 38. FRANCE LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 39. FRANCE LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 40. FRANCE LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 41. UK LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 42. UKLUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 43. UK LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 44. ITALY LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 45. ITALY LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 46. ITALY LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 47. SPAIN LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 48. SPAIN LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 49. SPAIN LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 50. REST OF EUROPE LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 51. REST OF EUROPE LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 52. REST OF EUROPE LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 53. EUROPE LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 54. EUROPE LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 55. EUROPE LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 56. ASIA-PACIFIC LUNG INJURY MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 57. JAPAN LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 58. JAPAN LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 59. JAPAN LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 60. CHINA LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 61. CHINA LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 62. CHINA LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 63. AUSTRALIA LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 64. AUSTRALIA LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 65. AUSTRALIA LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 66. INDIA LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 67. INDIA LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 68. INDIA LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 69. SOUTH KOREA LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 70. SOUTH KOREA LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 71. SOUTH KOREA LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 72. REST OF ASIA-PACIFIC LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 73. REST OF ASIA-PACIFIC LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 74. REST OF ASIA-PACIFIC LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 75. ASIA-PACIFIC LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 76. ASIA-PACIFIC LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 77. ASIA-PACIFIC LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 78. LAMEA LUNG INJURY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 79. BRAZIL LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 80. BRAZIL LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 81. BRAZIL LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 82. SAUDI ARABIA LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 83. SAUDI ARABIA LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 84. SAUDI ARABIA LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 85. SOUTH AFRICA LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 86. SOUTH AFRICA LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 87. SOUTH AFRICA LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 88. REST OF LAMEA LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 89. REST OF LAMEA LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 90. REST OF LAMEA LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 91. LAMEA LUNG INJURY MARKET, BY THERAPY, 2020-2030
TABLE 92. LAMEA LUNG INJURY MARKET, BY INJURY TYPE, 2020-2030
TABLE 93. LAMEA LUNG INJURY MARKET, BY END USER, 2020-2030
TABLE 94. APEPTICO: COMPANY SNAPSHOT
TABLE 95. APEPTICO: OPERATING SEGMENTS
TABLE 96. APEPTICO: PRODUCT PORTFOLIO
TABLE 97. APEPTICO: KEY DEVELOPMENTS
TABLE 98. BAYER: COMPANY SNAPSHOT
TABLE 99. BAYER: OPERATING SEGMENTS
TABLE 100. BAYER: PRODUCT PORTFOLIO
TABLE 101. BAYER: KEY DEVELOPMENTS
TABLE 102. GE: COMPANY SNAPSHOT
TABLE 103. GE: PRODUCT SEGMENTS
TABLE 104. GE: PRODUCT PORTFOLIO
TABLE 105. GSK: COMPANY SNAPSHOT
TABLE 106. GSK: PRODUCT SEGMENTS
TABLE 107. GSK: PRODUCT PORTFOLIO
TABLE 108. PHILIPS: COMPANY SNAPSHOT
TABLE 109. PHILIPS: PRODUCT SEGMENTS
TABLE 110. PHILIPS: PRODUCT PORTFOLIO
TABLE 111. PHILIPS: KEY DEVELOPMENTS
TABLE 112. LINDE: COMPANY SNAPSHOT
TABLE 113. LINDE: OPERATING BUSINESS SEGMENTS
TABLE 114. LINDE: PRODUCT PORTFOLIO
TABLE 115. MEDTRONIC: COMPANY SNAPSHOT
TABLE 116. MEDTRONIC: OPERATING SEGMENTS
TABLE 117. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 118. ONY: COMPANY SNAPSHOT
TABLE 119. ONY: OPERATING SEGMENTS
TABLE 120. ONY: PRODUCT PORTFOLIO
TABLE 121. PFIZER: COMPANY SNAPSHOT
TABLE 122. PFIZER: OPERATING BUSINESS SEGMENTS
TABLE 123. PFIZER: PRODUCT PORTFOLIO
TABLE 124. TEVA: COMPANY SNAPSHOT
TABLE 125. TEVA: OPERATING SEGMENTS
TABLE 126. TEVA: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. LUNG INJURY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021 (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. MODERATE THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE COMPETITIVE RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF LUNG INJURY MEDICATION MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. LUNG INJURY PHARMACOTHERAPY MARKET, 2020-2030 ($MILLION)
FIGURE 15. LUNG INJURY FLUID MANAGEMENT MARKET, 2020-2030 ($MILLION)
FIGURE 16. LUNG INJURY INHALED NITRIC OXIDE MARKET, 2020-2030 ($MILLION)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF LUNG INJURY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. LUNG INJURY MECHANICAL VENTILATION MARKET, 2020-2030 ($MILLION)
FIGURE 19. LUNG INJURY ADJUNCTIVE PROCEDURES DEVICES (ECMO) MARKET, 2020-2030 ($MILLION)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DIRECT LUNG INJURY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF INDIRECT LUNG INJURY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22. COMPARATIVE ANALYSIS OF LUNG INJURY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23. COMPARATIVE ANALYSIS OF LUNG INJURY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24. BAYER: NET SALES, 2018-2020 ($MILLION)
FIGURE 25. BAYER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26. BAYER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 27. GE: NET SALES, 2018-2020 ($MILLION)
FIGURE 28. GE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29. GE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 30. GSK: NET SALES, 2018-2020 ($MILLION)
FIGURE 31. GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32. GSK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 33. PHILIPS: NET SALES, 2018-2020 ($MILLION)
FIGURE 34. PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35. PHILIPS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 36. LINDE: NET SALES, 2018-2020 ($MILLION)
FIGURE 37. LINDE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38. MEDTRONIC: NET SALES, 2018-2020 ($MILLION)
FIGURE 39. MEDTRONIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40. MEDTRONIC: REVENUE SHARE BY REGION, 2020(%)
FIGURE 41. PFIZER: NET SALES, 2018-2020 ($MILLION)
FIGURE 42. PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43. TEVA: NET SALES, 2018-2020 ($MILLION)
FIGURE 44. TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45. TEVA: REVENUE SHARE BY REGION, 2020(%)
Companies Mentioned
- Apeptico Forschung Und Entwicklung GmBH
- Bayer AG
- General Electric Company
- Glaxosmithkline Plc,
- Koninklijke Philips N.V.
- Linde Plc.
- Medtronic Plc.
- Ony Biotech Inc
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
